Exchange: NASDAQ·Updated 07:59 PM EST

PYXS News

News
all
press releases
This Tesla Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Analysts upgraded Pyxis Oncology, PDD Holdings, Telus, Tesla and Banner, raising targets for PDD, Telus, Tesla and Banner.read more...
Benzinga
This Tesla Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Analysts upgraded Pyxis Oncology, PDD Holdings, Telus, Tesla and Banner, raising targets for PDD, Telus, Tesla and Banner.read more...
Benzinga
More News
HC Wainwright reissued a "buy" rating and set a $8.00 price objective on shares of Pyxis Oncology in a report on Friday...
MarketBeat
William Blair upgraded Pyxis Oncology from a "market perform" rating to an "outperform" rating in a research note on Friday...
MarketBeat
Pyxis Oncology, Inc. (PYXS) Discusses Updated MICVO Phase I Monotherapy Data in Head and Neck Cancer Transcript...
SeekingAlpha
Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.read more...
Benzinga
Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday's clinical data webcast.read more...
Benzinga
In trading on Tuesday, drugs shares were relative leaders, up on the day by about 2%. Leading the group were shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Pyxis Oncology up about 18.7% on the day. Also showing relative strength are gas utilities shares, up...
Nasdaq News: Markets
Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Approximately 4.0% of the company's stock are...
MarketBeat
Wall Street Zen upgraded shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Monday...
MarketBeat
Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...
MarketBeat

Advertisement|Remove ads.